This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
In recent years, the prevalence of tick-borne encephalitis virus (TBEV) has increased, and more endemic areas have been reported.4
TicoVac® offers TBE vaccination based on over two decades of clinical experience in Europe.5,6
Overall field effectiveness in regularly vaccinated persons in Austria having received the primary series was 96–99% for the years 2000–2011.2,6,7
TicoVac® may help protect against the main TBE virus subtypes found in nature.3 Three main subtypes of TBE exist across Europe and Asia: European, Siberian, and Far Eastern.8 It is difficult to know which subtype your patients will come in contact with, so helping to protect against the main subtypes is important.
Tick-borne Encephalitis is a disease caused by a virus that can be spread by a bite from an infected tick or through consumption of unpasteurized dairy products.1
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.